Tubulis
Tubulis

Revolutionary Munich Company Doses First Patient with Groundbreaking Cancer Treatment
BIOT
📢 Tubulis from Munich doses first patient with its ADC candidate TUB-040 targeting NaPi2b antigen in ovarian and lung cancer. 🧪
Tubulis

📢 Tubulis from Munich doses first patient with its ADC candidate TUB-040 targeting NaPi2b antigen in ovarian and lung cancer. 🧪